Competing interests
This study was funded by Ipsen (Boulogne, France). DW: received personal fees from Ipsen and grants from Siemens Healthineers. HG: received research grants from Abbvie, Intercept, ARLA Food for Health, and ADS AIPHIA Development Services AG; received consulting fees from Ipsen, NOVO, and Pfizer; lectures for AstraZeneca and EISAI; and serves on the Data Monitoring Committee at IQVIA. CA: received personal and consulting fees from Novartis/AAA. SN and JMB: received honoraria and/or consulting fees from Ipsen and Novartis/AAA. BP and AM: received consulting fees from Ariceum and were employed by Ipsen at the time of study initiation and conduct. ML: received research grants from Ipsen, NordicNanovector, Novartis, and PentixaPharm. DP and MV: employees of Ipsen. RJH: shares in Telix Pharmaceuticals. No other conflicts of interest exist.